Literature DB >> 24252784

Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly.

Stacy E Croteau1, Harry P W Kozakewich2, Antonio R Perez-Atayde2, Steven J Fishman3, Ahmad I Alomari4, Gulraiz Chaudry4, John B Mulliken5, Cameron C Trenor6.   

Abstract

OBJECTIVE: To describe the clinical and imaging characteristics of a new lymphatic disorder with a unique histological pattern and poor prognosis. STUDY
DESIGN: An observational, retrospective study identified and characterized 20 patients with distinct lymphatic histopathology referred to the Vascular Anomalies Center at Boston Children's Hospital between 1995 and 2011.
RESULTS: The median age at onset was 6.5 years (range, birth to 44 years). Clinical and radiologic findings suggested a generalized process. The most common presentations were respiratory symptoms (50%), hemostatic abnormalities (50%), and an enlarging, palpable mass (35%). All patients had mediastinal involvement; 19 patients developed pericardial (70%) and/or pleural effusions (85%). Extrathoracic disease manifested in bone and spleen and less frequently in abdominal viscera, peritoneum, integument, and extremities. Despite aggressive procedural and medical therapies, the 5-year survival was 51% and the overall survival was 34%. Mean interval between diagnosis and death was 2.75 years (range, 1-6.5 years).
CONCLUSIONS: We describe a clinicopathologically distinct lymphatic anomaly. We propose the term kaposiform lymphangiomatosis (KLA) because of characteristic clusters or sheets of spindled lymphatic endothelial cells accompanying malformed lymphatic channels. The intrathoracic component is most commonly implicated in morbidity and mortality; however, extrathoracic disease is frequent, indicating that KLA is not restricted to pulmonary lymphatics. The mortality rate of KLA is high despite aggressive multimodal therapy.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  GLA; Generalized lymphatic anomaly; KHE; KLA; Kaposiform hemangioendothelioma; Kaposiform lymphangiomatosis; MRI; Magnetic resonance imaging

Mesh:

Year:  2013        PMID: 24252784      PMCID: PMC3946828          DOI: 10.1016/j.jpeds.2013.10.013

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

1.  Kasabach-Merritt syndrome: treatment with epsilon-aminocaproic acid and assessment by indium 111 platelet scintigraphy.

Authors:  B L Shulkin; L C Argenta; K J Cho; V P Castle
Journal:  J Pediatr       Date:  1990-11       Impact factor: 4.406

2.  Residual lesions after Kasabach-Merritt phenomenon in 41 patients.

Authors:  O Enjolras; J B Mulliken; M Wassef; I J Frieden; P N Rieu; P E Burrows; A Salhi; C Léauté-Labreze; H P Kozakewich
Journal:  J Am Acad Dermatol       Date:  2000-02       Impact factor: 11.527

3.  Use of 111In platelet scans in the detection and treatment of Kasabach-Merritt syndrome.

Authors:  P M Sondel; M W Ritter; D G Wilson; L M Lieberman
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

Review 4.  Periorbital lymphatic malformation: clinical course and management in 42 patients.

Authors:  Arin K Greene; Patricia E Burrows; Lois Smith; John B Mulliken
Journal:  Plast Reconstr Surg       Date:  2005-01       Impact factor: 4.730

5.  Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis.

Authors:  L R Zukerberg; B J Nickoloff; S W Weiss
Journal:  Am J Surg Pathol       Date:  1993-04       Impact factor: 6.394

6.  Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics.

Authors:  J B Mulliken; J Glowacki
Journal:  Plast Reconstr Surg       Date:  1982-03       Impact factor: 4.730

7.  Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma.

Authors:  Lisa L Lyons; Paula E North; Fernand Mac-Moune Lai; Mark H Stoler; Andrew L Folpe; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2004-05       Impact factor: 6.394

8.  Diffuse pulmonary lymphangiomatosis.

Authors:  H D Tazelaar; D Kerr; S A Yousem; M J Saldana; C Langston; T V Colby
Journal:  Hum Pathol       Date:  1993-12       Impact factor: 3.466

Review 9.  Thoracic lymphangiomatosis in a child.

Authors:  Ofelia A Alvarez; Ingrid Kjellin; Craig W Zuppan
Journal:  J Pediatr Hematol Oncol       Date:  2004-02       Impact factor: 1.289

10.  Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine.

Authors:  Camille Haisley-Royster; Odile Enjolras; Ilona J Frieden; Maria Garzon; Margaret Lee; Arnold Oranje; Peter C J de Laat; Gerard C Madern; Francisco Gonzalez; Hayder Frangoul; Philippe Le Moine; Neil S Prose; Denise M Adams
Journal:  J Pediatr Hematol Oncol       Date:  2002 Aug-Sep       Impact factor: 1.289

View more
  33 in total

1.  Pseudotumor cerebri in kaposiform lymphangiomatosis: a case report and pathogenetic hypothesis.

Authors:  Cristina Barceló-López; Antonio L López-Guerrero; Antonio García-López; José Hurtado-Marín; Helena Alarcón-Martínez; Juan F Martínez-Lage
Journal:  Childs Nerv Syst       Date:  2018-04-13       Impact factor: 1.475

2.  Imaging features of kaposiform lymphangiomatosis.

Authors:  Pradeep Goyal; Ahmad I Alomari; Harry P Kozakewich; Cameron C Trenor; Antonio R Perez-Atayde; Steven J Fishman; Arin K Greene; Raja Shaikh; Gulraiz Chaudry
Journal:  Pediatr Radiol       Date:  2016-04-06

3.  Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.

Authors:  Elisa Boscolo; Patricia Pastura; Kathryn Glaser; Jillian Goines; Adrienne M Hammill; Denise M Adams; Peter Dickie; Belinda Hsi Dickie; Timothy D Le Cras
Journal:  Pediatr Blood Cancer       Date:  2019-05-02       Impact factor: 3.167

4.  Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.

Authors:  Kiersten W Ricci; Adrienne M Hammill; Paula Mobberley-Schuman; Stephen C Nelson; Julie Blatt; Julia L Glade Bender; Catherine C McCuaig; Anna Synakiewicz; Ilona J Frieden; Denise M Adams
Journal:  Pediatr Blood Cancer       Date:  2019-01-22       Impact factor: 3.167

5.  Isolation of human lymphatic endothelial cells by multi-parameter fluorescence-activated cell sorting.

Authors:  Zerina Lokmic; Elizabeth S Ng; Matthew Burton; Edouard G Stanley; Anthony J Penington; Andrew G Elefanty
Journal:  J Vis Exp       Date:  2015-05-01       Impact factor: 1.355

6.  Medical therapy for pediatric vascular anomalies.

Authors:  Judith F Margolin; Heather Mills Soni; Sheena Pimpalwar
Journal:  Semin Plast Surg       Date:  2014-05       Impact factor: 2.314

7.  Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies.

Authors:  Denise M Adams; Cameron C Trenor; Adrienne M Hammill; Alexander A Vinks; Manish N Patel; Gulraiz Chaudry; Mary Sue Wentzel; Paula S Mobberley-Schuman; Lisa M Campbell; Christine Brookbank; Anita Gupta; Carol Chute; Jennifer Eile; Jesse McKenna; Arnold C Merrow; Lin Fei; Lindsey Hornung; Michael Seid; A Roshni Dasgupta; Belinda H Dickie; Ravindhra G Elluru; Anne W Lucky; Brian Weiss; Richard G Azizkhan
Journal:  Pediatrics       Date:  2016-01-18       Impact factor: 7.124

8.  Kasabach-Merritt syndrome combined with hypercalcemia: A case report.

Authors:  Runying Zou; Fang Peng; Tian Yu; Saizhen Zeng; Yalan You; Keke Chen; Hui Zou; Xin Tian; Chengguang Zhu; Xiangling He
Journal:  Exp Ther Med       Date:  2017-10-18       Impact factor: 2.447

9.  MR imaging findings of vertebral involvement in Gorham-Stout disease, generalized lymphatic anomaly, and kaposiform lymphangiomatosis.

Authors:  Hiroki Kato; Michio Ozeki; Toshiyuki Fukao; Masayuki Matsuo
Journal:  Jpn J Radiol       Date:  2017-08-09       Impact factor: 2.374

10.  Kaposiform hemangioendothelioma without cutaneous involvement.

Authors:  Yi Ji; Siyuan Chen; Lizhi Li; Kaiying Yang; Chunchao Xia; Li Li; Gang Yang; Feiteng Kong; Guoyan Lu; Xingtao Liu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-06       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.